Celularity Inc Cash Flow Statement
CELU|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Celularity Inc used $13M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$91.7M | -$57.9M | -$196.3M | $14.2M | -$100.1M |
| Depreciation & Amortization | $7.3M | $7.9M | $9.3M | $9.4M | $8.8M |
| Operating Cash Flow | -$13.3M | -$6.4M | -$38.7M | -$137.9M | -$110.1M |
| Capital Expenditures | - | $161.0K | $1.0M | $5.2M | $6.2M |
| Free Cash Flow | - | -$6.6M | -$39.7M | -$143.1M | -$116.3M |
| FCF Margin | - | -12.1% | -174.5% | -796.2% | -545.1% |